Correction: Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis

Ji-Nuo Wang; Ting Liu; Ai-Lin Zhao; Bo-Ju Pan; Jian Sun; Jian Li; Dao-Bin Zhou; Xin-Xin Cao; Ming-Hui Duan

doi:10.1038/s41375-023-01812-4

Correction: Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis

Leukemia. 2023 Mar;37(3):723. doi: 10.1038/s41375-023-01812-4.

Authors

Ji-Nuo Wang^#¹, Ting Liu^#¹, Ai-Lin Zhao¹, Bo-Ju Pan^{2

3}, Jian Sun^{2

3}, Jian Li^{1

3}, Dao-Bin Zhou^{1

3}, Xin-Xin Cao^{4

5}, Ming-Hui Duan^{6

7}

Affiliations

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China.
² Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China.
³ State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, 100730, Beijing, China.
⁴ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China. [email protected].
⁵ State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, 100730, Beijing, China. [email protected].
⁶ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China. [email protected].
⁷ State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, 100730, Beijing, China. [email protected].

^# Contributed equally.

PMID: 36755128
DOI: 10.1038/s41375-023-01812-4

No abstract available

Publication types

Published Erratum